Polymorphisms of STS gene and SULT2A1 gene and neurosteroid levels in Han Chinese boys with attention-deficit/hyperactivity disorder: an exploratory investigation

Liang-Jen Wang1,2, Wen-Ching Chan3, Miao-Chun Chou1, Wen-Jiun Chou1, Min-Jing Lee1, Sheng-Yu Lee4,5, Pao-Yen Lin6, Yi-Hsin Yang7 & Cheng-Fang Yen2,8

This study examined the relationships among polymorphisms of the STS gene and SULT2A1 gene, dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S), and characteristics of attention-deficit/hyperactivity disorder (ADHD). We used cheek swabs to obtain the genomic DNA of 200 ADHD male probands (mean age: 8.7 years), 192 patients’ mothers and 157 patients’ fathers. Three SNPs in the STS gene (rs6639786, rs2270112, and rs17268988) and one SNP in the SULT2A1 gene (rs182420) were genotyped. Saliva samples were collected from the ADHD patients to analyze DHEA and DHEA-S levels. The behavioral symptoms were evaluated with the Swanson, Nolan, and Pelham, and Version IV Scale for ADHD (SNAP-IV), and the neuropsychological function was assessed using the Conners’ Continuous Performance Tests (CPT). We found the C allele of rs2270112 within the STS gene to be over-transmitted in males with ADHD. Polymorphisms of rs182420 within the SULT2A1 gene were not associated with ADHD. In addition, the C allele carriers of rs2270112 demonstrated significantly higher DHEA-S levels than the G allele carriers. Levels of DHEA were positively correlated with attention as measured by the CPT. These findings support a potential role in the underlying biological pathogenesis of ADHD with regard to STS polymorphisms and neurosteroid levels.

Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that affects approximately 3–10% school-age children around the world1,2. The core symptoms of ADHD are inattention, hyperactivity, and impulsivity, all of which have a significantly negative impact on patients’ functioning3. Although the underlying pathophysiological mechanisms of ADHD are complex and multidimensional, neurosteroids have been connected with ADHD susceptibility4. Dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S) are important neurosteroid substrates that are critical for various physiological processes and involved in several neuropsychiatric diseases5. DHEA(S) may facilitate neurite extension and neural cell proliferation and is thus important for regulating neurodevelopment6,7. Furthermore, DHEA(S) exerts stimulatory or antagonistic

1Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 2Department of Psychiatry, School of Medicine, and Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 3Center for Research Informatics, The University of Chicago, Chicago, Illinois, 60637, United States of America. 4Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 5Department of Psychiatry, College of Medicine and Hospital, National Cheng Kung University, Tainan, Taiwan. 6Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 7School of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 8School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Correspondence and requests for materials should be addressed to C.-F.Y. (email: chfaye@cc.kmu.edu.tw)
effects at gamma-aminobutyric acid (GABAₐ) receptors and facilitates N-methyl-D-aspartate (NMDA) activity. DHEA and DHEA-S levels in blood are inversely related to the severity of hyperactivity/impulsivity symptoms in young male with ADHD. We previously reported that salivary DHEA levels were significantly lower in ADHD patients than those in healthy controls. Furthermore, DHEA(S) levels in ADHD patients increased significantly while they underwent medication treatment. Therefore, DHEA(S) is considered a potential biomarker for ADHD.

The sex discrepancy in many ADHD characteristics is significant. The prevalence of ADHD is significantly higher in males (the ratios of boys to girls range from 2:1 to 9:1). Previous research into ADHD has established a strong genetic component to the phenotype. The significantly higher incidence of males suffering from the disorder suggests that some susceptibility genes may lie on the X chromosome. The steroid sulfatase (STS) gene, located at Xp22.32, encodes a multi-pass membrane protein of the endoplasmic reticulum. The protein is the property of sulfatase family, and is involved in the pathway that converts neurosteroid sulfates into their free forms (e.g., DHEA-S to DHEA). Several animal studies have revealed that the 39,X(Y)*O mice with deletion of the STS gene exhibit abnormal behaviors and cognitive functions that are relevant to the inattention and hyperactivity that many ADHD patients experience. The ADHD-like features seemed to be correlated with the dysregulation of steroid hormone levels and neurotransmitters, and improvement may be triggered through administration with DHEA-S.

In humans, the STS gene is correlated with androgen synthesis and metabolism, while STS deficiency has been proposed as a risk factor for ADHD. Chatterjee et al. reported a link between X-linked ichthyosis (STS deficiency) and ADHD diagnosis/symptoms. Brookes et al. performed the transmission disequilibrium test (TDT) analysis, which produced two single nucleotide polymorphisms (SNPs) that were overtransmitted in patients with ADHD in the Caucasian population. Recently, five more SNPs on the STS gene (C allele at rs1473666, T allele at rs6639786, T allele at rs5934769, G allele at rs5934770, and G allele at rs1733568), as well as an allele specific haplotype of 12 SNPs, were found to be significantly associated with ADHD. Furthermore, Stergiakouli et al. reported that G allele at rs17268988 was related to inattentive symptoms, while polymorphisms within STS were related to cognitive performance among ADHD males. However, said association between STS polymorphisms and ADHD has not yet been examined in a non-Caucasian population.

The SULT2A1 gene, located at 19q13.3, encodes a member of the sulfotransferase family, and functions as a catalyst for the sulfate conjugation of DHEA and other steroids. In this way, the SULT2A1 gene may participate in ADHD pathophysiology. Garcia-Anguita et al. indicated that the polymorphisms in the SULT2A1 gene (rs2637125 and rs182420) may affect DHEA-S concentration in post-pubertal healthy boys. Although a genome-wide association study (GWAS) revealed that genetic variants of SULT2A1 do not affect individuals’ DHEA(S) concentrations or the DHEA/DHEAS ratio, such association was never investigated in individuals with ADHD. Therefore, whether genetic variants of SULT2A1 influence neurosteroid and further correlate to ADHD susceptibility remains unclear.

Evidence has already established that the STS and SULT2A1 genes are vital for catalyzing neurosteroids (DHEA or DHEA-S) metabolism, which may participate in ADHD pathophysiology. However, little is known about the relationship among variants of the STS gene and the SULT2A1 gene, DHEA(S) levels, and ADHD characteristics. Genetic associations for complex diseases may be probed either with case-control studies of unrelated people or with family-based designs. Relative to case-control designs, family-based study designs (e.g. case-parent trios) have the advantage that there is a common genetic background among the family members and may be applicable for detecting risk genes of ADHD. To fill in the research gap, this study used a family-based design to investigate the relationships among polymorphisms of the STS gene and SULT2A1 gene, salivary DHEA(S) levels, and ADHD characteristics.

Methods

Participants. The study protocol was approved by the Institutional Review Board of Chang Gung Hospital in Taiwan (IRB No: 101-4835A3). All procedures performed in this study involving participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki Declaration. We obtained written informed consent from the parents or guardians of all the participating children.

We recruited eligible outpatients with ADHD receiving treatment at the Department of Child Psychiatry at Kaohsiung Chang Gung Memorial Hospital in Taiwan. The admisibility criteria for entry into this study were as follows: (1) patients aged between 6 and 16 years who met the criteria for ADHD outlined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV); (2) without a history of neuropsychiatric diseases (such as intellectual disabilities, autism spectrum disorder, bipolar disorders, major depressive disorders, psychotic disorders, substance dependence, epilepsy, or severe head trauma); (3) without any known major physical illnesses (such as genetic, metabolic, or infectious conditions) that require surgical intervention or long-term medication; (4) either newly diagnosed with ADHD or had an existing diagnosis but had not taken medication for ADHD for at least the prior 6 months; (5) of ethnic Han Chinese origin; and (6) with at least one biological parent that can provide the check swab sample and complete this study’s assessment. A total of 208 boys (mean age of 8.7 ± 2.1 years) met the inclusion criteria and agreed to participate in this study.

Study Procedures. Patients were interviewed by a child psychiatrist using the Chinese version of the Schedule for Affective Disorder and Schizophrenia for School-Age Children, Epidemiologic Version (K-SADS-E). The social and behavioral competence and ADHD symptoms of patients were evaluated with the Swanson, Nolan, and Pelham Questionnaire, Version IV for ADHD (SNAP-IV), which the patients’ parents and teachers completed. The ADHD patients then performed the Wechsler Intelligence Scale for Children-Fourth Edition.
(WISC-IV), and the Conners’ Continuous Performance Tests (CPT) were performed by an experienced psychologist in a dedicated room for testing so that test condition variability was minimized. Patients’ parents were asked to fill out the 18-question Adult ADHD Self-Report Scale (ASRS).

High molecular weight genomic DNA of ADHD patients and their biological parents were extracted from cheek swabs using routine procedures. The ADHD patients’ saliva samples were collected between 7:00 and 8:00 am using the passive drool method in order to analyze the neuroendocrine substrate levels. Patients were instructed to avoid excessive physical activity during the preceding 24 h and to fast overnight prior to saliva collection.

Genotyping. The genotyping of three SNPs in the STS gene (rs6639786 and rs2270112 in intron 1 and rs17268988 in intron 9) has been carried out in previous literature using custom allelic discrimination TaqMan assays (Applied Biosystems, Foster City, CA, USA). According to genotype data in the HapMap Project (www.hapmap.org), the Han Chinese population has no reported polymorphisms for rs5934770, rs12861247, or rs17335568. Therefore, these SNPs were not considered for further analyses in this study.

The polymorphism rs182420 in the SULT2A1 gene has been genotyped in previous literature using custom allelic discrimination TaqMan assays (Applied Biosystems, Foster City, CA, USA). The allele frequency of rs2637125 was reported to have a great disparity (G/A:0.99/0.01) in the Han Chinese population in the HapMap Project. Therefore, the polymorphism of rs2637125 was also removed from this study. A 7500 Fast RealTime PCR System (Applied Biosystems) was used to make allelic discrimination decisions.

Laboratory Tests for Neurosteroid Levels. Saliva was put in collecting tubes, immediately placed on ice, and stored at −80°C until assayed. We used an enzyme immunoassay (ELISA) to determine and quantify the DHEA in saliva (IB79306, IBL International GmbH) and also used an ELISA for the in-vitro diagnostic quantitative determination of DHEA-S (RES2661/RES2669, IBL International GmbH). The detection range of these methods for DHEA and DHEA-S was 2.2–1440 pg/ml and ≥0.05 ng/mL, respectively. The intra- and inter-assay coefficients of variation were 3.4–4.7% and 3.1–5.6% for DHEA and ≤7.8% and ≤14.9% for DHEA-S.

Behavioral and Neuropsychological Assessment. The K-SADS-E is a semi-structured diagnostic interview designed to assess current and past episodes of psychopathology in children and adolescents according to DSM-III-R and DSM-IV criteria. The K-SADS-E is administered by interviewing the parent(s) and the child to ultimately determine summary ratings that include all sources of information.

The SNAP-IV is a 26-item questionnaire used to evaluate ADHD symptoms and severity. The 26 items include 18 items related to ADHD symptoms (9 for inattention and 9 for hyperactivity and impulsivity) and 8 pertaining to oppositional defiant disorder symptoms as defined in the DSM-IV-TR. The Chinese version of the SNAP-IV parent form and the SNAP-IV teacher form have been reported to have satisfactory levels of reliability and concurrent validity.

The ASRS is a self-administered questionnaire that evaluates ADHD symptoms in adults. The two-part questionnaire consists of inattention and hyperactivity/impulsivity subscales, each of which has nine indications that have persisted for at least 6 months. The validity and reliability of the Chinese version of ASRS have been confirmed through previous studies. Whether the parents had ADHD or not was determined using the ASRS, and the total score of the ASRS > 16 were classified as ADHD cases.

The WISC-IV is an individually administered and norm-referenced tool that aims to measure intelligence in children aged from 6 to 16. The WISC-IV contains 10 core and 5 supplemental subtests. The core subtests are used to form four factor indexes, including the Verbal Comprehension Index (VCI), the Perceptual Reasoning Index (PRI), the Working Memory Index (WMI), and the Processing Speed Index (PSI). The Chinese version of the WISC-IV has been validated by prior studies.

The CPT is a 14-minute computerized test that mainly judges attention and impulse control. In short, participants have to respond to the stimuli on a computer screen by pressing a space bar for every letter except the letter “X.” The test includes various assessment parameters, including Omissions, Commissions, Hit Reaction Time (RT), Hit Reaction Time Standard Error (Hit RT SE), Variability of Standard Error, and Detectability (D’). The T-score of each index was used for research analyses, and a lower T-score represents a better performance. Finally, a Confidence Index (percentile) integrates all the CPT data obtained from the test’s administration to provide a probability out of 100 that a significant attention problem exists.

Statistical Analyses. Data were analyzed using the Statistical Package for the Social Sciences for Windows (version 16.0; SPSS, Inc., Chicago, IL, USA). Variables are presented as either mean ± standard deviation (SD) or frequency.

The transmission disequilibrium test (TDT) was originally developed to test for the transmission of associated marker locus by studying case-parent trios from a heterozygous parent to an affected child. In this study, TDT analysis was conducted using PLINK v1.90b3.38 (7 Jun 2016) and was applied to the collection of trio data in this study. Odds ratio, chi-square statistic, and p-value were calculated for each allele of interest.

Because data on the DHEA and DHEA-S levels exhibited significant positive skewness and violated normal distribution, and the case numbers of the minor allele carriers were small, non-parametric statistics were used to analyze the data. Genotypes of the SNPs (rs6639786, rs2270112, and rs17268988) within STS gene were classified based on the allele identified on X-chromosome, and genotypes of rs182420 in the SULT2A1 gene were classified into C/T or T/T. Metric variables between genotypes were tested using the t-test or the Mann-Whitney U test. The Mann-Whitney U test was used to determine the potential difference in neurosteroid levels between patients with different genotypes. Spearman’s correlation coefficient was used to investigate the relationship between...
neurosteroid levels and ADHD characteristics. Two-tailed p-values < 0.05 were considered statistically significant. Bonferroni correction was further performed to adjust for multiple testing in the correlation matrix.

### Results

Of the 208 ADHD boys recruited in this study, 200 patients provided their genomic DNA with a cheek swab; the saliva samples of 160 patients were successfully collected; and 173 patients completed the clinical and neuropsychological assessments. Table 1 lists the characteristics of the 200 boys whose genomic DNA data were available (mean ages of 8.7 ± 2.1 year). We found that C allele carriers of rs2270112 had significantly lower SNAP-IV oppositional scores rated by teachers (p = 0.014) than G allele carriers. However, salivary DHEA levels and DHEA-S/DHEA ratios were not significantly different between patients with various genotypes.

The relationships of salivary neurosteroid levels and ADHD characteristics are provided in Table 3. Salivary DHEA levels showed a significant negative correlation with many indices of CPT, including Confidence Index (r = −0.25, p = 0.002), Omission (r = −0.23, p = 0.005), Hit RT (r = −0.23, p = 0.004), Hit RT SE (r = −0.26, p = 0.002), and SNAP-IV Teacher form (O) (r = 0.24, p = 0.004). The other two SNP markers located in the SULT2A1 gene were not associated with ADHD (Table 2).

The salivary DHEA, DHEA-S levels and DHEA-S/DHEA ratios between polymorphisms of the SUT2A1 gene and SULT2A1 gene are shown in Fig. 1. The C allele carrier of rs2270112 had significantly higher DHEA-S levels (mean difference = 0.85 ng/ml, p = 0.014) than the G allele carrier. However, salivary DHEA levels and DHEA-S/DHEA ratios were not significantly different between patients with various genotypes.

### Table 1. Characteristics of boys with attention-deficit/hyperactivity disorder, and comparisons of different genotypes.

| Characteristics | Total (N = 200) | C allele (n = 50) | T allele (n = 150) | G allele (n = 179) | C/T (n = 22) | T/T (n = 163) |
|-----------------|-----------------|------------------|-------------------|------------------|-------------|-------------|
| **Age (year)**  | 8.7 ± 2.1       | 8.8 ± 2.2        | 8.7 ± 2.1         | 8.8 ± 2.1        | 8.6 ± 2.1   | 8.7 ± 2.2   |
| **WISC-IV**     |                |                  |                   |                  |             |             |
| FSIQ            | 95.0 ± 12.6     | 94.3 ± 13.0      | 95.4 ± 12.6       | 98.3 ± 7.6       | 94.6 ± 12.9 | 96.2 ± 11.8 |
| VCI             | 98.9 ± 12.4     | 100.0 ± 13.5     | 98.6 ± 11.9       | 99.1 ± 9.4       | 98.8 ± 12.5 | 99.0 ± 12.9 |
| PRI             | 95.8 ± 15.2     | 92.4 ± 16.0      | 97.5 ± 15.1       | 98.0 ± 5.8       | 95.3 ± 15.7 | 97.9 ± 14.1 |
| WMI             | 95.9 ± 13.6     | 93.1 ± 13.2      | 97.2 ± 14.3       | 98.5 ± 10.9      | 95.6 ± 14.1 | 96.8 ± 14.7 |
| PSI             | 93.3 ± 14.3     | 91.5 ± 12.3      | 92.0 ± 14.7       | 99.4 ± 13.6      | 92.7 ± 14.0 | 93.3 ± 12.0 |
| **Clinical measures** |              |                  |                   |                  |             |             |
| SNAP-IV parent form (I) | 14.6 ± 5.5 | 14.8 ± 5.4 | 14.8 ± 5.7 | 13.6 ± 6.0 | 14.9 ± 5.5 | 13.9 ± 5.5 |
| SNAP-IV parent form (H) | 12.9 ± 6.0 | 13.4 ± 5.6 | 12.6 ± 6.3 | 11.4 ± 5.5 | 13.1 ± 6.0 | 12.8 ± 5.4 |
| SNAP-IV parent form (O) | 10.7 ± 5.8 | 11.0 ± 5.3 | 10.3 ± 5.9 | 8.3 ± 5.4  | 10.8 ± 5.8 | 10.8 ± 5.8 |
| SNAP-IV teacher form (I) | 14.6 ± 6.2 | 13.6 ± 5.9 | 14.5 ± 6.4 | 11.9 ± 6.8 | 14.7 ± 6.2 | 15.4 ± 6.3 |
| SNAP-IV teacher form (H) | 11.9 ± 7.4 | 11.7 ± 6.8 | 11.9 ± 7.6 | 9.6 ± 8.9 | 12.1 ± 7.2 | 12.3 ± 7.3 |
| SNAP-IV teacher form (O) | 7.7 ± 6.3 | 8.0 ± 5.7 | 7.5 ± 6.4 | 4.6 ± 4.9 | 7.9 ± 6.2** | 7.9 ± 6.4 |
| **Index of CPT** |                  |                  |                   |                  |             |             |
| Confidence Index (%) | 61.2 ± 22.3 | 59.9 ± 21.0 | 62.5 ± 23.0 | 66.5 ± 26.0 | 61.1 ± 22.3 | 61.6 ± 21.3 |
| Omission | 62.0 ± 29.9 | 59.2 ± 30.4 | 64.1 ± 31.4 | 72.7 ± 44.8 | 61.2 ± 27.9 | 58.2 ± 20.4 |
| Commission | 49.9 ± 10.6 | 50.0 ± 11.0 | 50.0 ± 10.7 | 49.9 ± 10.4 | 49.8 ± 10.7 | 50.9 ± 9.9 |
| Hit Reaction Time | 55.6 ± 12.9 | 55.8 ± 12.5 | 55.8 ± 13.1 | 57.2 ± 14.5 | 55.7 ± 12.6 | 55.0 ± 10.7 |
| Hit Reaction Time SE | 58.0 ± 12.0 | 57.6 ± 11.7 | 58.8 ± 11.9 | 61.5 ± 14.0 | 58.0 ± 11.6 | 58.3 ± 10.2 |
| Variability | 58.1 ± 11.3 | 56.6 ± 10.6 | 59.2 ± 12.2 | 61.7 ± 11.7 | 57.9 ± 11.1 | 58.1 ± 10.7 |
| Detectability | 51.6 ± 9.8 | 51.9 ± 10.8 | 51.6 ± 9.4 | 56.6 ± 8.3** | 50.9 ± 9.8 | 51.3 ± 9.0 |

*Z = 1.980, p = 0.048; ^Z = 2.425, p = 0.015; ^Z = 2.733, p = 0.006.}
p = 0.001), and Variability (r = −0.22, p = 0.008). If we used Bonferroni correction to adjust for multiple testing in the correlation matrix (p-value = 0.05/13 = 0.0038), DHEA levels were only significantly correlated to Confidence Index and Hit RT SE. We observed no significant correlations between salivary DHEA(S) levels and behavioural symptoms.

**Discussion**

Our results reveal that rs2270112 within the STS gene was over-transmitted in Han Chinese boys with ADHD. Polymorphisms of rs182420 within the SULT2A1 gene were not associated with ADHD. Since the C allele of
rs2270112 within the STS gene was over-transmitted in males with ADHD, we explored whether rs2270112 polymorphisms influence STS gene function, reflected by patients’ neurosteroids levels. Among boys with ADHD, the C allele carriers of rs2270112 had significantly higher DHEA-S levels than the G allele carriers. In addition, we found that the salivary levels of DHEA were correlated with several neuropsychological indices measured by the CPT.

To the best of our knowledge, this study is the first to investigate the genetic variants of the STS gene and the SULT2A1 gene in ADHD among a non-Caucasian population. A previous study using family-based design indicated that as many as seven polymorphisms within the STS gene were significantly associated with ADHD. Furthermore, another study using case-control design found three SNPs within the STS gene were associated with cognitive function in ADHD males. In contrast, we found that only one SNP (rs2270112) of the STS gene was over-transmitted in ADHD boys. The inconsistent findings may be attributed to discrepancies of sample size, study designs, or possible ethnic differences in genetic variants. For example, several SNPs of the STS gene that have been associated with Caucasian ADHD patients do not exhibit polymorphisms in the Han Chinese population. Additionally, it has been reported that the G allele at rs17268988 is the minor allele, whereas we found the C allele is the minor allele of this SNP among our study population. Therefore, the findings of previous genetic studies conducted in the Caucasian population may not be universally applied across ethnicities. However, these results support the hypothesis of previous literature that ADHD susceptibility is associated with variants or functions of the STS gene in males with ADHD.

We found that the C allele of rs2270112 at STS gene was significantly associated with higher DHEA-S levels in boys with ADHD. The STS protein is a microsomal enzyme that converts DHEA-S into its unsulfated form of DHEA, which participates in a neurosteroid biosynthesis pathway of the brain. Current evidence related to how STS genetic variants affect DHEA(S) concentrations is still scarce. Relative to previous investigations, the current study is advanced in providing data about DHEA, DHEA-S and DHEA-S/DHEA ratios specific in ADHD population. In addition, we performed comprehensive assessments for patients’ behavioural symptoms and neuropsychological function (CPT). By demonstrating the association between the rs2270112 within the STS gene with the synthesis or transformation of DHEA(S) levels in patients with ADHD, our result suggest the rs2270112 may be linked to the neurobiology pathogenesis of ADHD.

Our study’s results reveal that the polymorphisms of rs182420 in the SULT2A1 gene were not associated with ADHD, and did not influence the salivary DHEA or DHEA-S levels in ADHD boys. However, Garcia-Anguita et al. indicated that 792 healthy post-pubertal (12–16-year-old) boys homoyzous for the allele of rs182420 (TT) showed higher DHEA-S concentration than heterozygous TC boys, followed by CC boys. These contradictory findings may be to the result of ethnic differences, discrepancies in target populations, or sample sizes. For example, no participants carried a CC genotype of rs182420 in our study population, which indicates that the variants distribution of the SULT2A1 gene may differ between ethnicities. The SULT2A1 gene has been reported as a catalyst for the sulfate conjugation of DHEA. Nevertheless, data regarding whether the genotypes of SULT2A1 appear to have effects on individuals’ DHEA(S) have been inconsistent in previous studies. Our data did not support that SULT2A1 gene plays a role in the susceptibility of ADHD.
The results of this study show that several indexes measured by CPT were positively correlated with salivary DHEA levels, particularly Confidence Index and Hit RT SE. These findings are in line with our previous investigations in which an independent cohort was recruited. The Confidence Index represents the probability that an overall attention problem exists, and the Hit RT SE indicates the consistency of response times for responses to target. In animal studies, 39(X;Y)O mice exhibit deficits in the performance of 5-choice serial reaction time task (5-CSRTT), whereas DHEA-S administration could reverse these deficits under attentional demanding conditions. The 5-CSRTT, a rodent analogue of the human CPT, is a laboratory behavioral task for assessing neurobiological substrates of attention. Therefore, compatible with our findings, previous data in mice have suggested a link between attention and DHEA(S) levels. The protective effects of DHEA(S) on patients' neuropsychological function may account for enhancing neuron growth, regulating GABA, and NMDA activity, or modulating the complex process of cortical maturation during middle childhood. DHEA and DHEA-S may also play independent roles in some aspects of the nervous system. For example, DHEA-S is better at improving neuronal survival and stimulating catecholamine synthesis and secretion; in contrast, DHEA outperforms DHEA-S in neurogenesis. We proposed that DHEA may exert certain neuropsychological functions among boys with ADHD. Nevertheless, although the CPT provides an objective assessment for attention, the neurocognitive deficits measured by the CPT may not be specific to ADHD. Whether the relationships between DHEA levels and CPT performance were specific for ADHD patients warrants further investigation.

The subjects recruited in our study were all males. Compelling evidence have revealed that male and female ADHD patients have distinct clinical manifestations, neuropsychological functions and response to medication treatment. Various neurobiological domains have been proposed to underlie the sex differences in attention and impulsivity, including neurosteroids and their associated genes. Future studies are required to explore whether STS and SULT2A1 genes also play a role in female ADHD patients.

This study has several limitations. First, the case number was small, and that reduced statistic power lowers the likelihood of finding a potential association between genetic variants and ADHD. Second, the target SNPs of the STS gene and SULT2A1 gene in this study were chosen based on the findings of previous literature. However, several SNPs that have been found to be associated with ADHD in Caucasian populations did not exhibit polymorphisms in our Han-Chinese study sample. Therefore, advanced techniques, such as next-generation sequencing, may be more beneficial for discovering the genetic variants associated with ADHD. Third, the diagnoses of ADHD for the parents were determined using the ASRS, lacking validation using structural diagnostic instruments. Thus, it is possible that some patients' parents were misclassified as either case or control. Therefore, the current study result should be interpreted with caution. Fourth, multiple testing correction was not performed in the statistical analyses. If Bonferroni correction had been performed to adjust for multiple testing in the correlation matrix (Tables 2 and 3), few of our significant findings would remain. Finally, we used saliva samples to measure the neurosteroid levels in this study. Although a previous study demonstrated that hormone concentrations in plasma, urine, saliva, and hair are highly correlated, the DHEA(S) levels measured in saliva may not necessarily represent the concentration and activity of neurosteroids in the brain.

In conclusion, our findings suggest that STS gene polymorphisms and DHEA(S) levels may related to ADHD susceptibility. Among Han Chinese boys with ADHD, polymorphisms of rs2270112 within the STS gene were over-transmitted, and are associated with DHEA-S concentration. Salivary levels of DHEA were positively correlated with attention measured by a neuropsychological test. Future research with a considerably larger sample size is needed to determine how neurosteroids and their associated genes are involved in the underlying biological mechanisms of ADHD.

References
1. Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C. & Rohde, L. A. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. *Int J Epidemiol* **43**, 434–442 (2014).
2. Gau, S. S., Chong, M. Y., Chen, T. H. & Cheng, A. T. A. A 3-year panel study of mental disorders among adolescents in Taiwan. *Am J Psychiatry* **162**, 1344–1350 (2005).
3. Polanczyk, G. V. & Moffitt, T. E. How evidence on the developmental nature of attention-deficit/hyperactivity disorder can increase the validity and utility of diagnostic criteria. *J Am Acad Child Adolesc Psychiatry* **53**, 723–725 (2014).
4. Dubrovsky, B. O. Steroids, neuroactive steroids and neurosteroids in psychopathology. *Prog Neuropsychopharmacol Biol Psychiatry* **29**, 169–192 (2005).
5. Maninger, N., Wołkowitz, O. M., Reus, V. I., Epel, E. S. & Mellon, S. H. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). *Front Neuroendocrinol* **30**, 65–91 (2009).
6. Golubchik, P. et al. Neurosteroids in child and adolescent psychopathology. *Eur Neuropsychopharmacol* **17**, 157–164 (2007).
7. Rahmani, A., Shoae-Hassani, A., Keyhani, P., Kheradmand, D. & Darbandi-Azar, A. Dehydroepiandrosterone stimulates nerve growth factor and brain derived neurotrophic factor in cortical neurons. *Adv Pharmacol Sci* **2013**, 506191 (2013).
8. Strous, R. D., Maayan, R. & Weizman, A. The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside. *Eur Neuropsychopharmacol* **16**, 153–169 (2006).
9. Strous, R. D. et al. Analysis of neurosteroid levels in attention deficit hyperactivity disorder. *Int J Neuropsychopharmacol* **4**, 259–264 (2001).
10. Wang, L. J. et al. Salivary dehydroepiandrosterone, but not cortisol, is associated with attention deficit hyperactivity disorder. *World J Biol Psychiatry* **12**, 99–109 (2011).
11. Maayan, R. et al. Three-month treatment course of methylphenidate increases plasma levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) in attention deficit hyperactivity disorder. *Neuropsychobiology* **48**, 111–115 (2003).
12. Lee, M. S. et al. Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention deficit hyperactivity disorder. *Child Psychiatry Hum Dev* **39**, 201–209 (2008).
13. Wang, L. J. et al. Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate. *Psychoneuroendocrinology* **36**, 1209–1216 (2011).
14. Molina-Carballido, A. et al. Differential responses of two related neurosteroid genes to methylphenidate based on ADHD subtype and the presence of depressive symptomatology. *Psychopharmacology (Berl)* **231**, 3635–3645 (2014).
15. Scassellati, C., Bonvicini, C., Faraone, S. V. & Gennarelli, M. Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. *J Am Acad Child Adolesc Psychiatry* **51**, 1003–1019 e1020 (2012).
16. Faraone, S. V. et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57, 1313–1323 (2005).
17. Rhee, S. H. & Waldman, I. D. Etiology of sex differences in the prevalence of ADHD: an examination of inattention and hyperactivity-impulsivity. Am J Med Genet B Neuropsychiatr Genet 127B, 60–64 (2004).
18. NCBI. STS steroid sulfatase [(human)] https://www.ncbi.nlm.nih.gov/gene/412 (2017).
19. Reed, M. J., Purohit, A., Woo, L. W., Newman, S. P. & Potter, B. V. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 26, 171–202 (2005).
20. Mortaud, S. et al. Brain pathways mediating the pro-aggressive effect of the steroid sulfatase (Sts) gene. Behav Genet 40, 211–219 (2010).
21. Davies, W., Humpy, T., Isles, A. R., Burgoyne, P. S. & Wilkinson, L. S. X-monosomy effects on visuospatial attention in mice: a candidate gene and implications for Turner syndrome and attention deficit hyperactivity disorder. Biol Psychiatry 61, 1351–1360 (2007).
22. Davies, W. et al. Converging pharmacological and genetic evidence indicates a role for steroid sulfatase in attention. Biol Psychiatry 66, 360–367 (2009).
23. Trent, S. et al. Biological mechanisms associated with increased perseveration and hyperactivity in a genetic mouse model of neurodevelopmental disorder. Psychoneuroendocrinology 38, 1370–1380 (2013).
24. Trent, S. et al. Steroid sulfatase-deficient mice exhibit endophenotypes relevant to attention deficit hyperactivity disorder. Psychoneuroendocrinology 37, 221–229 (2012).
25. Davies, W. et al. Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD. Neuropsychopharmacology 39, 2622–2632 (2014).
26. Idkowiak, J. et al. Steroid Sulfatase Deficiency and Androgen Activation Before and After Puberty. J Clin Endocrinol Metab 101, 2549–2553 (2016).
27. Kent, L. et al. X-linked idiochyrosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication disorder. J Med Genet 45, 519–524 (2008).
28. Chatterjee, S., Humpy, T. & Davies, W. Behavioural and Psychiatric Phenotypes in Men and Boys with X-Linked Idiochyrosis: Evidence from a Worldwide Online Survey. PloS One 11, e0164417 (2016).
29. Brooks, K. J. et al. Association of the steroid sulfatase (STS) gene with attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B, 1531–1535 (2008).
30. Brooks, K. J. et al. Polymorphisms of the steroid sulfatase (STS) gene are associated with attention deficit hyperactivity disorder and influence brain tissue mRNA expression. Am J Med Genet B Neuropsychiatr Genet 153B, 1417–1424 (2010).
31. Stergioulou, E. et al. Steroid sulfatase is a potential modulator of cognition in Attention Deficit Hyperactivity Disorder. Genes Brain Behav 10, 334–341 (2011).
32. NCBI. SULT2A1 sulfotransferase family 2A member 1 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/6822 (2017).
33. Thomae, B. A., Eckloff, B. W., Freimuth, R. R., Wieben, E. D. & Weinshilboum, R. M. Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J 2, 48–56 (2002).
34. Garcia-Anguita, A., Ortega, L. & Garces, C. Relationship between polymorphisms in the sulfotransferase SULT2A1 gene and dehydroepiandrosterone sulfate concentration in children. Exp Biol Med (Maywood) 238, 163–166 (2013).
35. Haring, R. et al. A SULT2A1 genetic variant identified by GWAS as associated with low serum DHEAS does not impact on the actual DHEA/DHEAS ratio. J Mol Endocrinol 50, 73–77 (2013).
36. Evangeliou, E., Trikalinos, T. A., Salanti, G. & Ioannidis, J. P. Family-based versus unrelated case-control designs for genetic associations. PLoS Genet 2, e123 (2006).
37. Nsenigmana, J. & Bishop, D. T. Design considerations for genetic linkage and association studies. Methods Mol Biol 850, 237–262 (2012).
38. Kaufman, J. et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36, 980–988 (1997).
39. Gau, S. F. & Soong, W. T. Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: a case-control study. Aust N Z J Psychiatry 33, 734–739 (1999).
40. Bussing, R. et al. Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample. Assessment 15, 317–328 (2008).
41. Gau, S. S. et al. Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale - parent form. Int J Methods Psychiatr Res 17, 35–44 (2008).
42. Gau, S. S. et al. Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, Version IV Scale-Teacher Form. J Pediatr Psychol 34, 850–861 (2009).
43. Murphy, P. & Schachar, R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 157, 1156–1159 (2000).
44. Gau, S. S. et al. Association between sleep problems and symptoms of attention-deficit/hyperactivity disorder in young adults. Sleep 30, 195–201 (2007).
45. Kessler, R. C. et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 35, 245–256 (2005).
46. Baron, I. S. Test review: Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV). Child Neuropsychol 11, 471–475 (2005).
47. Yang, P. et al. Wechsler Intelligence Scale for Children 4th edition-Chinese version index scores in Taiwanese children with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci 67, 83–91 (2013).
48. Conners, C. K. The computerized continuous performance test. Psychopharmacol Bull 21, 891–892 (1985).
49. Conners, C. K. Interpreting Results in Conners’s Continuous Performance Test II (CPT II) for Windows Technical Guide and Software Manual (ed. Conners, C. K.) 25–33 (MHS, 2004).
50. Spelman, R. S., McGinnis, R. E. & Ewens, W. J. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 52, 506–516 (1993).
51. NCBI. Reference SNP (rs) Cluster Report: rs17268988 https://www.ncbi.nlm.nih.gov/gene/projects/SNP/rs17268988 (2017).
52. Goodarzi, M. O., Antoine, H. J. & Azziz, R. Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. J Clin Endocrinol Metab 92, 2659–2664 (2007).
53. Louweryn, V. et al. Variants in SULT2A1 affect the DHEA sulfate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype. J Clin Endocrinol Metab 98, 3848–3855 (2013).
54. Trent, S., Fry, J. P., Ojairkere, O. A. & Davies, W. Altered brain gene expression but not steroid biochemistry in a genetic mouse model of neurodevelopmental disorder. Mol Autism 5, 21 (2014).
55. Robbins, T. W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163, 362–380 (2002).
56. Callahan, P. M. & Terry, A. V. Jr. Attention. Handb Exp Pharmacol 228, 161–189 (2015).
57. Nguyen, T. V. et al. Interactive effects of dehydroepiandrosterone and testosterone on cortical thickness during early brain development. J Neurosci 33, 10840–10848 (2013).
58. Nguyen, T. V. et al. The developmental relationship between DHEA and visual attention is mediated by structural plasticity of cortico-amygdalar networks. Psychoneuroendocrinology 70, 122–133 (2016).
59. Brewer, G. J. et al. Culture and regeneration of human neurons after brain surgery. J Neurosci Methods 107, 15–23 (2001).
60. Ziegler, C. G. et al. Dehydroepiandrosterone induces a neuroendocrine phenotype in nerve growth factor-stimulated chromaffin pheochromocytoma PC12 cells. Endocrinology 149, 320–328 (2008).
61. Suzuki, M., Wright, L. S., Marwha, P., Lardy, H. A. & Svendsen, C. N. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 101, 3202–3207 (2004).
62. Epstein, J. N. et al. Relations between Continuous Performance Test performance measures and ADHD behaviors. J Abnorm Child Psychol 31, 543–554 (2003).
63. Edwards, M. C. et al. Estimates of the validity and utility of the Conners’ Continuous Performance Test in the assessment of inattentive and/or hyperactive-impulsive behaviors in children. J Abnorm Child Psychol 35, 393–404 (2007).
64. Gerston, J. A meta-analytic review of gender differences in ADHD. J Atten Disord 5, 143–154 (2002).
65. Rucklidge, J. I. Gender differences in attention-deficit/hyperactivity disorder. Psychiatric Clin North Am 33, 357–373 (2010).
66. Cornforth, C., Sonuga-Barke, E. & Coghill, D. Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients. Curr Pharm Des 16, 2424–2433 (2010).
67. Hasson, R. & Fine, J. G. Gender differences among children with ADHD on continuous performance tests: a meta-analytic review. J Atten Disord 16, 190–198 (2012).
68. Wang, L. J., Shen, C. K. & Huang, Y. S. Gender Differences in the Behavioral Symptoms and Neuropsychological Performance of Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate: A Two-Year Follow-up Study. J Child Adolesc Psychopharmacol 25, 501–508 (2015).
69. Trent, S. & Davies, W. The influence of sex-linked genetic mechanisms on attention and impulsivity. Biol Psychol 89, 1–13 (2012).
70. Davies, W. Sex differences in Attention Deficit Hyperactivity Disorder: Candidate genetic and endocrine mechanisms. Front Neuroendocrinol 35, 331–346 (2014).
71. Wang, W., Hu, W., Hou, F., Hu, P. & Wei, Z. SNVerGUI: a desktop tool for variant analysis of next-generation sequencing data. J Med Genet 49, 753–755 (2012).
72. Gaudl, A. et al. Liquid chromatography quadrupole linear ion trap mass spectrometry for quantitative steroid hormone analysis in plasma, urine, saliva and hair. J Chromatogr A 1464, 64–71 (2016).

Acknowledgements
This work was supported by the Taiwan National Science Council (NSC 102-2314-B-182A-009), the Taiwan Ministry of Science and Technology (MOST 103-2314-B-182A-017), and the Chang Gung Memorial Hospital Research Projects (CMRPG8E0561 and CMRPG8E0571). The authors would like to thank Professor Wei-Tsun Soong for granting us the use of the Chinese version of the K-SADS and Professor Shur-Fen Gau for granting our use of the Chinese version of the SNAP-IV.

Author Contributions
L.J.W. wrote the first draft. W.C.C. and S.Y.L. managed the lab work and statistics. L.J.W., M.C.C., W.J.C., and M.J.L. managed participant recruitment. P.Y.L. assisted the protocol development. Y.H.Y. and C.F.Y. supervised this work and edited the manuscript. All authors reviewed the manuscript.

Additional Information
Competing Interests: The authors declare no competing financial interests.

How to cite this article: Wang, L.-J. et al. Polymorphisms of STS gene and SULT2A1 gene and neurosteroid levels in Han Chinese boys with attention-deficit/hyperactivity disorder: an exploratory investigation. Sci. Rep. 7, 45595; doi: 10.1038/srep45595 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017